Get started
Author

Koji Date

Observed names: K Date, K. Date, KOJI DATE
ORCID: 0000-0002-1283-4083
Observed ORCID: 0000-0002-1283-4083
OpenAlex ID: A5001070993
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
2023 · Hayato Kawachi, Tadaaki Yamada, et al. · JAMA Network Open · 33
PDF
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients
2019 · Akihiro Yoshimura, Tadaaki Yamada, et al. · Translational Lung Cancer Research · 30
PDF
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
2022 · Yusuke Chihara, Takayuki Takeda, et al. · The Oncologist · 15
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
2024 · Hayato Kawachi, Tadaaki Yamada, et al. · OncoImmunology · 12
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy
2023 · Kenji Morimoto, Tadaaki Yamada, et al. · Drugs & Aging · 12
YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
2024 · Yuki Katayama, Tadaaki Yamada, et al. · Clinical Cancer Research · 11
[Prevention of arthralgia and myalgia from paclitaxel and carboplatin combination chemotherapy with Shakuyaku-kanzo-to].
2000 · H Fujiwara, T Urabe, et al. · PubMed · 11
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study
2023 · Kenji Morimoto, Tadaaki Yamada, et al. · Targeted Oncology · 10
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study
2022 · Kenji Morimoto, Tadaaki Yamada, et al. · JTO Clinical and Research Reports · 10
PDF
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
2025 · Kenji Morimoto, Tadaaki Yamada, et al. · Lung Cancer · 9
PDF
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study
2024 · Naoya Nishioka, Hayato Kawachi, et al. · Frontiers in Immunology · 8
PDF
Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer
2019 · Yusuke Chihara, Akihiro Yoshimura, et al. · The Oncologist · 8
PDF
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
2024 · Yusuke Tachibana, Kenji Morimoto, et al. · Investigational New Drugs · 5
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%
2024 · Shota Takei, Hayato Kawachi, et al. · Frontiers in Immunology · 5
PDF
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study
2023 · Masaki Ishida, Kenji Morimoto, et al. · JTO Clinical and Research Reports · 4
A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer
2018 · Akihiro Yoshimura, Yusuke Chihara, et al. · The Oncologist · 4
PDF
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer
2018 · Yusuke Chihara, Koji Date, et al. · Investigational New Drugs · 4
Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan
2025 · Shiho Goda, Tadaaki Yamada, et al. · Scientific Reports · 3
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure
2025 · Kenji Morimoto, Tadaaki Yamada, et al. · Targeted Oncology · 2
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
2023 · Kenji Morimoto, Tadaaki Yamada, et al. · Targeted Oncology · 2
A Case of Small Cell Lung Cancer Presenting with Severe Liver Injury due to Diffuse Liver Metastases Which Was Successfully Treated with Early Chemotherapy
2020 · Kenji Morimoto, Yoshie Morimoto, et al. · Haigan · 2
PDF
A Case of Lung Cancer with Peritoneal Carcinomatosis Effectively Treated with Docetaxel
2019 · Kenji Morimoto, Koji Date, et al. · Haigan · 2
PDF
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer
2018 · YOSHIZUMI TAKEMURA, YUSUKE CHIHARA, et al. · Anticancer Research · 2
PDF
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study
2025 · Kenji Morimoto, Tadaaki Yamada, et al. · International Journal of Clinical Oncology · 1
Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression
2025 · K. Morimoto, T. Yamada, et al. · ESMO Real World Data and Digital Oncology · 1
PDF
Works count: 47
Citation count: 208
H-index: 9
I10-index: 9
Year
Topic
Type